| Literature DB >> 24782714 |
Kelsey L Clark1, Behrad Noudoost1.
Abstract
While much progress has been made in identifying the brain regions and neurochemical systems involved in the cognitive processes disrupted in mental illnesses, to date, the level of detail at which neurobiologists can describe the chain of events giving rise to cognitive functions is very rudimentary. Much of the intense interest in understanding cognitive functions is motivated by the hope that it might be possible to understand these complex functions at the level of neurons and neural circuits. Here, we review the current state of the literature regarding how modulations in catecholamine levels within the prefrontal cortex (PFC) alter the neuronal and behavioral correlates of cognitive functions, particularly attention and working memory.Entities:
Keywords: V4; dopamine; extrastriate cortex; frontal eye field; pathophysiology; reward; top-down control
Mesh:
Substances:
Year: 2014 PMID: 24782714 PMCID: PMC3986539 DOI: 10.3389/fncir.2014.00033
Source DB: PubMed Journal: Front Neural Circuits ISSN: 1662-5110 Impact factor: 3.492
Studies examining the contribution of prefrontal catecholamines to the behavioral and neural correlates of working memory in non-human primates.
Studies are divided by neuromodulator (dopamine or norepinephrine) and specific receptor (D1R, D2R, alpha-2A) where applicable. Abbreviations: MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which kills dopaminergic neurons in the substantia nigra; 5-OHDA, 5-hydroxydopamine, which selectively kills dopaminergic and noradrenergic neurons; FEF, Frontal Eye Field; dlPFC, dorsolateral prefrontal cortex; vlPFC, ventrolateral prefrontal cortex; SNR, signal-to-noise ratio; MGS, memory-guided saccade.
Figure 1DA modulates the efficacy of synaptic connections within PFC. (A) Cartoon illustrates a characteristic “synaptic triad” in monkey PFC: the same spine (S) is postsynaptic to both a DA-positive axon (DA) and a non-immunoreactive axon terminal (non-DA). The synapse of the DA axon is symmetric, while the non-DA axon forms an asymmetric synapse. Based on electron micrography and immunostaining of synaptic connections in layer II of monkey PFC (from Goldman-Rakic et al., 1989). (B) D1R signaling alters synaptic efficacy, a measured by changes in the synchronous firing of pairs of PFC neurons. Castner and Williams (2007) simultaneously recorded from pairs of neurons in monkey PFC before and after delivering a D1R agonist or antagonist using in vivo iontophoresis. Cross-correlograms depict the number of spikes occurring at a particular time-lag relative to spikes of the other neuron in the pair: a peak at 0 ms indicates simultaneous firing due to common input. The top pair of PFC neurons exhibited a 0 ms peak prior to drug infusion (gray): application of a D1R agonist eliminated this peak (red), presumably by disrupting the efficacy of common input. In the bottom plot, the neurons did not show evidence of common input during the control recordings (gray), but a peak emerged following application of a D1R antagonist (red), reflecting stronger or more reliable excitation from their common inputs. (C) Effects of D1R agonists and antagonists on working memory performance will depend on initial levels of PFC DA. Gray curves illustrate working memory performance as a function of PFC DA level: performance is greatest at an intermediate level, with insufficient or excessive DA leading to impaired performance. Basal DA levels (illustrated by the dashed lines) are usually tuned for optimal performance (middle curve), but are sub-optimal in aged animals (back curve), and above optimal in the case of stress (front curve). D1R agonists (red arrows) and antagonists (blue arrows) effect working memory performance differently based on initial DA levels: if initial DA levels are supra-optimal, as in stress, then D1R antagonists will move DA signaling toward the optimal level, improving performance, while agonists will further impair performance. If initial DA levels are below optimal, as in aged animals, then D1R agonists will increase DA signaling back toward optimal levels, improving performance; D1R antagonists will move DA levels further from optimal, impairing performance.
Figure 2Interactions between attention and reward. (A) A schematic illustration of typical tasks used to study reward and attention, and how the differences in potential reward and neural activity are similar between the two paradigms. Consider two studies conducted in V1 (Stănişor et al., 2013 and McAdams and Reid, 2005). To study the effect of reward size in the Stănişor task (schematically illustrated in the top panel), two potential targets appear, with colors indicating different reward values. Neural activity recorded at this point in the task reflects the relative value of the target in the RF (higher activity when the RF target offered a greater reward than the non-RF target); a subsequent cue instructs the monkey which target to saccade to. In the McAdams and Reid attentional paradigm (bottom panel), a cue indicates which of two stimuli should be monitored for a change, which instructs an eye movement response to a separate location. Changes at the uncued location must be ignored, and will never lead to rewards. Neural activity is higher when the stimulus in the RF is cued. In both cases higher expected reward value for the stimulus in the RF is associated with greater neural activity. (B) An overview of brain areas in which neural activity reflecting both attentional modulation and reward value has been reported. Only a single study is cited for each area; reward studies are in gray, attention studies in black. Dotted outlines represent structures not located on the cortical surface, either within sulci or deeper within the brain. Abbreviations: PMC, premotor cortex; vlPFC, ventrolateral prefrontal cortex; dlPFC, dorsolateral prefrontal cortex; SC, superior colliculus; BG, basal ganglia; LIP, lateral intraparietal area; SEF, supplementary eye field; ACC, anterior cingulate cortex; FEF, frontal eye field.
Figure 3The effects of PFC DA on visual cortical activity. Manipulating D1R-mediated FEF activity enhances visual representations in area V4. Noudoost and Moore (2011b) infused a D1R antagonist into the FEF while recording from V4 neurons with RFs either overlapping or not overlapping the area of space represented at the site of drug infusion; the visual responses of the same V4 neurons were recorded before and after infusion of drugs into the FEF. FEF RF center was estimated based on the endpoints of microstimulation-evoked saccades. FEF D1R manipulation caused an increase in orientation selectivity, increase in response magnitude, and decrease in response variability at overlapping V4 sites (orange bars); no effect was seen for non-overlapping V4 sites (green), or saline infusions (gray). These changes in V4 responses with FEF D1R manipulation mimic those seen during covert attention. *p <0.05.
Studies examining the contribution of prefrontal catecholamines to the behavioral and neural correlates of working memory in human subjects.
Studies are grouped based on methodology: drug administration, PET, effects of genetic polymorphisms, and medication withdrawal in Parkinson's patients. Abbreviations and drug actions: DA, dopamine; bromocriptine, a D2 agonist; pergolide, an agonist for both D1 and D2 receptors; haloperidol, non-specific DA agonist; methylphenidate, amphetamine, and dextroamphetamine: stimulants producing an increase in PFC DA and NE release; sulpiride, D2 antagonist; guanfacine, alpha-2A agonist; clonidine, alpha-2 agonist; SCH23390, D1 receptor antagonist; DAT1, dopamine transporter gene; COMT, catechol-O-methyltransferase gene; 5-HTT, serotonin transporter gene; DARPP-32, dopamine- and cAMP-regulated neuronal phosphoprotein gene; DRD2, dopamine receptor D2 gene; WM, working memory; PET, positron emission tomography; dlPFC, dorsolateral prefrontal cortex.